

EsoGuard[®]
esophageal DNA test

DNA screening for precursors of esophageal cancer




Detect altered DNA

With over 90% sensitivity and specificity at detecting BE and EAC, the EsoGuard esophageal DNA test allows detection of these conditions in a simple office-based procedure without endoscopy.¹

Barrett's Esophagus screening rates are very low — even for the high-risk patients

Over 90%
of Esophageal Adenocarcinoma patients never knew they had treatable Barrett's Esophagus²

Esophageal Adenocarcinoma has increased over 733% in the past 4 decades³



Less than 10%
of high-risk GERD patients currently undergo EGD screening⁴

Multiple factors contribute to the low BE screening rate, even in high-risk patients, including limited patient awareness of the relationship between GERD and EAC and guidelines recommending BE screening as well as reluctance to refer patients, whose symptoms may be reasonably controlled on PPIs for an “invasive” endoscopic procedure.



~40% of EAC patients
were asymptomatic prior to diagnosis⁵

Lethal Cancer
less than 20% 5 year survival⁶

Find Barrett's *before* it progresses

EsoGuard esophageal DNA test is a highly accurate test that detects altered DNA to help diagnose precursors of esophageal cancer.



EsoGuard is a laboratory developed test that has demonstrated over 90% specificity and 90% sensitivity in diagnosing Barrett's Esophagus.¹

The assay uses next generation sequencing (NGS) to examine individual DNA molecules for the presence or absence of cytosine methylation at 31 different genomic locations.

408

patient human study

published in
Science Translational Medicine¹

>90%

sensitivity & specificity

at detecting BE, with and without dysplasia,
as well as esophageal adenocarcinoma¹


EsoGuard analyzes methylation at 31 sites on 2 genes

EsoGuard assesses the presence of methylation in targeted regions of the Vimentin and CCNA1 genes after the samples have undergone bisulfite conversion—a chemical step which allows characterization of DNA methylation at CpG sites.


EsoGuard is used to detect non-dysplastic BE including short segment and long segment, dysplastic BE, including both low and high grade forms, adenocarcinoma of the esophagus including intramucosal disease, and adenocarcinoma of the gastroesophageal junction.

Know before you scope —
distal esophageal cells can be collected
in a simple office-based procedure


The assay provides a binary report which
means a clear result without pathology



What's in the EsoGuard kit




Test Requisition Form & Instructions




Scissors



Specimen Container



Biohazard Bag



Bubble Pouch



Return Mailer Box (Shipping Box)



Clear Sticker

How it works



01 Cell Collection

Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory.



02 Test

The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.



03 Results

The physician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.

REFERENCES:

1. Science Translational Medicine. 17 Jan 2018; Vol. 10, Issue 424, eaao5848, DOI: 10.1126/scitranslmed.aao5848
2. Gut 2015 Jan;64(1):20-5. doi: 10.1136/gutjnl-2013-305506. Epub 2014 Apr 3.
3. Thuy-Van P. Hang, MD; Zachary Spiritos, MD, MPH; Anthony Gamboa, MD; Zhengjia Chen, PhD; Seth Force, MD; Steve Keilin, MD; Nabil Saba, MD; Bassel El-Rayes, MD; Qiang Cai, MD, PhD; Field Willingham, MD, MPH. THE EPIDEMIOLOGY OF ESOPHAGEAL ADENOCARCINOMA IN THE UNITED STATES. Program No. P0265. ACG 2018 Annual Scientific Meeting Abstracts. Philadelphia, Pennsylvania: American College of Gastroenterology.
4. Deloitte Analysis, on file Lucid Dx
5. Mikolašević, I., Bokun, T., & Filipec Kanižaj, T. (2018). Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma - where do we stand?. Croatian medical journal, 59(3), 97-99. <https://doi.org/10.3325/cmj.2018.59.97>
6. <https://seer.cancer.gov/explorer/>

EsoGuard is a laboratory developed test available through a CLIA certified and CAP accredited laboratory. EsoGuard is a trademark of Lucid Diagnostics. © Lucid Diagnostics 2021.

AD-0195 Rev C



→ [LucidDx.com](https://www.lucid Dx.com)

[f](#) [t](#) [@](#) [in](#) @EsoGuard_Test

[EsoGuard.com](https://www.EsoGuard.com)